曲霉血浆游离DNA聚合酶链反应诊断侵袭性曲霉病的准确性优于血清半乳甘露聚糖
本研究回顾性比较了曲霉血浆游离DNA聚合酶链反应(cfDNA PCR)与血清半乳甘露聚糖诊断侵袭性曲霉病(IA)的性能,纳入238例疑似侵袭性真菌病患者,结果显示cfDNA PCR总体灵敏度86.0%、特异度93.1%,新诊断IA患者灵敏度93.0%,作者认为cfDNA PCR是比血清半乳甘露聚糖更灵敏的无创诊断替代方法。
要点
- 曲霉血浆cfDNA PCR诊断IA总体灵敏度86.0%、特异度93.1%。
- 新诊断IA患者中cfDNA PCR灵敏度93.0%。
- 血液恶性肿瘤/干细胞移植患者血清半乳甘露聚糖灵敏度67.9%、特异度89.8%。
核心结论
- 曲霉血浆cfDNA PCR是比血清半乳甘露聚糖更灵敏的无创诊断IA的替代方法。
研究设计与样本
- 回顾性研究,纳入2020年9月1日至2022年10月30日在Stanford Health Care接受曲霉血浆cfDNA PCR检测的所有疑似侵袭性真菌病患者。
- 共纳入238例有曲霉血浆cfDNA PCR结果的患者,包括63例阳性和175例非连续阴性。
- 根据EORTC/MSG定义将患者分为确诊、临床诊断、疑似和无IA。
主要发现
- 多数患者存在免疫抑制(89.9%),30天全因死亡率为22.3%。
- 曲霉血浆cfDNA PCR总体灵敏度为86.0%(37/43;95%CI 72.7-95.7),特异度为93.1%(121/130;95%CI 87.4-96.3)。
- 血液恶性肿瘤/干细胞移植患者血清半乳甘露聚糖灵敏度为67.9%(19/28;95%CI 49.3-82.1),特异度为89.8%(53/59;95%CI 79.5-95.3)。
- 新诊断IA患者中cfDNA PCR灵敏度为93.0%(40/43;95%CI 80.9-98.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive aspergillosis (IA) in immunocompromised hosts carries high morbidity and mortality. Diagnosis is often delayed because definitive diagnosis requires invasive specimen collection, while noninvasive testing with galactomannan is moderately accurate. Plasma cell-free DNA polymerase chain reaction (cfDNA PCR) represents a novel testing modality for the noninvasive diagnosis of invasive fungal disease (IFD). We directly compared the performance of Aspergillus plasma cfDNA PCR with serum galactomannan for the diagnosis of IA during routine clinical practice. METHODS: We conducted a retrospective study of all patients with suspected IFD who had Aspergillus plasma cfDNA PCR testing at Stanford Health Care from 1 September 2020 to 30 October 2022. Patients were categorized into proven, probable, possible, and no IA based on the EORTC/MSG definitions. Primary outcomes included the clinical sensitivity and specificity for Aspergillus plasma cfDNA PCR and galactomannan. RESULTS: Overall, 238 unique patients with Aspergillus plasma cfDNA PCR test results, including 63 positives and 175 nonconsecutive negatives, were included in this study. The majority were immunosuppressed (89.9%) with 22.3% 30-day all-cause mortality. The overall sensitivity and specificity of Aspergillus plasma cfDNA PCR were 86.0% (37 of 43; 95% confidence interval [CI], 72.7-95.7) and 93.1% (121 of 130; 95% CI, 87.4-96.3), respectively. The sensitivity and specificity of serum galactomannan in hematologic malignancies/stem cell transplants were 67.9% (19 of 28; 95% CI, 49.3-82.1) and 89.8% (53 of 59; 95% CI, 79.5-95.3), respectively. The sensitivity of cfDNA PCR was 93.0% (40 of 43; 95% CI, 80.9-98.5) in patients with a new diagnosis of IA. CONCLUSIONS: Aspergillus plasma cfDNA PCR represents a more sensitive alternative to serum galactomannan for noninvasive diagnosis of IA.
引用
- Mah J, Nicholas V, Tayyar R, et al. Superior Accuracy of Aspergillus Plasma Cell-Free DNA Polymerase Chain Reaction Over Serum Galactomannan for the Diagnosis of Invasive Aspergillosis. Clin Infect Dis. 2023. PMID: 37450614. doi:10.1093/cid/ciad420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。